Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | terminated | Phase 1 | 4 | Medical College of WisconsinOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02978235 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma | terminated | Phase 1 | 11 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03530683 |
| terminated |
| Phase 1 |
| 189 |
| PfizerINDUSTRY |
| 1 |
| Sep 3, 2024 |
| clinicaltrials |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 47 | CelgeneINDUSTRY | 5 | Aug 30, 2024 | clinicaltrials |
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 1 | 53 | Hoffmann-La RocheINDUSTRY | 6 | Aug 23, 2024 | clinicaltrials |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | terminated | Phase 1 / Phase 2 | 58 | Columbia UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | terminated | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 6 | Aug 15, 2024 | clinicaltrials |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT02091063 | ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | terminated | Phase 1 / Phase 2 | 23 | Jennifer AmengualOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | terminated | Phase 1 | 14 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | — | 350 | University of WashingtonOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04545333 | The clonoSEQ® Watch Registry | terminated | — | 465 | Adaptive BiotechnologiesINDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05908396 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 4 | IGM Biosciences, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03435250 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | terminated | Phase 1 | 123 | Institut de Recherches Internationales ServierOTHER | 3 | Jul 25, 2024 | clinicaltrials |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 97 | IGM Biosciences, Inc.INDUSTRY | 7 | Jul 24, 2024 | clinicaltrials |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | terminated | Phase 1 / Phase 2 | 20 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | terminated | — | 3 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | terminated | Phase 1 | 172 | TG Therapeutics, Inc.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | terminated | Phase 1 | 5 | Roncarolo, Maria Grazia, MDOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | terminated | Phase 1 / Phase 2 | 13 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | terminated | N/A | 24 | Washington University School of MedicineOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT00838955 | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 14 | Loyola UniversityOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | terminated | Phase 2 | 5 | Loyola UniversityOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02400242 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma | terminated | Phase 1 | 85 | CelgeneINDUSTRY | 5 | Jul 9, 2024 | clinicaltrials |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | terminated | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | terminated | Phase 1 / Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | terminated | Phase 1 / Phase 2 | 12 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03777410 | Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma | terminated | — | 33 | Travera IncINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | terminated | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | terminated | Phase 1 | 32 | Cartesian TherapeuticsINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | terminated | Phase 2 | 17 | Emory UniversityOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Allogene TherapeuticsINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03451825 | Phase I/II Study of Avelumab in Pediatric Cancer Participants | terminated | Phase 1 | 21 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Jun 24, 2024 | clinicaltrials |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | Altor BioScienceINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 38 | TakedaINDUSTRY | 9 | Jun 14, 2024 | clinicaltrials |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | Abdullah KhanOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05048732 | Imaging Apoptosis for Lymphoma Treatment Response | terminated | Early Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides(BDI) | terminated | N/A | 1 | Indiana UniversityOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 2 | University of ChicagoOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | terminated | N/A | 25 | Centre Hospitalier Henri Duffaut - AvignonOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | terminated | Phase 2 | 3 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials